Barclays Maintains an 'Overweight' on Vertex (VRTX); Raising PT to $77
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Price: $77.38 -2.65%
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Trade VRTX Now!
Barclays maintains an 'Overweight' on Vertex (NASDAQ: VRTX) price target raised from $44 to $77.
Analyst, Ying Huang, said, "...Based on the Phase III results of Kalydeco in patients with the G551D mutation, we believe the observed improvement in lung function is sustainable. Although we are puzzled by the sweat chloride data (reductions were not statistically significant between Day 28 and Day 56), ultimately lung function improvement is the most relevant, in terms of both regulatory approval and clinical significance."
"We project peak cystic fibrosis revenues of $5 billion. ~48% of all CF patients carry two copies of the F508del mutation while ~40% carry one copy, compared to 4% of all CF patients with the G551D mutation..."
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $58.12 yesterday, with a 52 week range of $26.50-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ying Huang, said, "...Based on the Phase III results of Kalydeco in patients with the G551D mutation, we believe the observed improvement in lung function is sustainable. Although we are puzzled by the sweat chloride data (reductions were not statistically significant between Day 28 and Day 56), ultimately lung function improvement is the most relevant, in terms of both regulatory approval and clinical significance."
"We project peak cystic fibrosis revenues of $5 billion. ~48% of all CF patients carry two copies of the F508del mutation while ~40% carry one copy, compared to 4% of all CF patients with the G551D mutation..."
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $58.12 yesterday, with a 52 week range of $26.50-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- Jefferies Downgrades Bed Bath & Beyond (BBBY) to Hold
- Best Buy (BBY) May Show Progress on Earnings Front, UBS Remains Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
